CORD-19:c654596857bce9cdd64ffc51842048643107348c / 394868-395222 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T3374","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"TextSentencer_T3375","span":{"begin":95,"end":354},"obj":"Sentence"},{"id":"T25461","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"T71869","span":{"begin":95,"end":354},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Pfizer Global Research and Development, Department of Discovery Biology, Sandwich, UK Purpose: The present study was designed to determine whether the activity of voriconazole (VOR), a novel triazole, was reduced against candidal and cryptococcal infections by the addition of standard antifungal agents, amphotericin B (AMB) and 5-fluorocytosine (5-FC)."}

{"project":"Epistemic_Statements","denotations":[{"id":"T513","span":{"begin":0,"end":354},"obj":"Epistemic_statement"}],"text":"Pfizer Global Research and Development, Department of Discovery Biology, Sandwich, UK Purpose: The present study was designed to determine whether the activity of voriconazole (VOR), a novel triazole, was reduced against candidal and cryptococcal infections by the addition of standard antifungal agents, amphotericin B (AMB) and 5-fluorocytosine (5-FC)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T374","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"T375","span":{"begin":95,"end":354},"obj":"Sentence"}],"text":"Pfizer Global Research and Development, Department of Discovery Biology, Sandwich, UK Purpose: The present study was designed to determine whether the activity of voriconazole (VOR), a novel triazole, was reduced against candidal and cryptococcal infections by the addition of standard antifungal agents, amphotericin B (AMB) and 5-fluorocytosine (5-FC)."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1920","span":{"begin":234,"end":257},"obj":"Disease"},{"id":"T64779","span":{"begin":234,"end":257},"obj":"Disease"}],"attributes":[{"id":"A1920","pred":"mondo_id","subj":"T1920","obj":"http://purl.obolibrary.org/obo/MONDO_0005724"},{"id":"A91643","pred":"mondo_id","subj":"T64779","obj":"http://purl.obolibrary.org/obo/MONDO_0005724"}],"text":"Pfizer Global Research and Development, Department of Discovery Biology, Sandwich, UK Purpose: The present study was designed to determine whether the activity of voriconazole (VOR), a novel triazole, was reduced against candidal and cryptococcal infections by the addition of standard antifungal agents, amphotericin B (AMB) and 5-fluorocytosine (5-FC)."}